Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Dent disease type 2 is a type of Dent disease in which patients have the manifestations of Dent disease type 1 associated with extra-renal features.
Features include always present findings: Low-molecular-weight proteinuria and Hypercalciuria; and common findings: Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Elevated circulating aspartate aminotransferase concentration, Aminoaciduria, and Elevated circulating alanine aminotransferase concentration and others. 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 4 |
OCRL encodes OCRL inositol polyphosphate-5-phosphatase (901 aa). Catalyzes the hydrolysis of the 5-position phosphate of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and phosphatidylinositol-3,4,5-bisphosphate (PtdIns(3,4,5)P3), with the greatest catalytic activity towards PtdIns(4,5)P2. Highest expression in Esophagus Gastroesophageal Junction (60.2 TPM) and Esophagus Muscularis (56.6 TPM).
Dent disease type 2 is associated with mutations in the OCRL gene on chromosome X.
The OCRL protein participates in RHOF GAPs stimulate RHOF GTPase activity and Endophilins recruit synaptojanins to the clathrin-coated pit pathways.
OCRL is classified as a druggable target (Druggable Genome and Enzyme categories) with score 7.5.
Dent disease should be suspected in an individual with the three criteria below in the absence of other known causes of proximal tubule dysfunction . Note: A possible diagnosis of Dent disease is considered if LMW proteinuria and at least one other criterion are present.
Source: GeneReviews — "Dent Disease"
No approved treatments are currently available for Dent disease type 2. The disease remains an area of unmet medical need.
To establish the extent of disease and needs of an individual diagnosed with Dent disease, the following evaluations are recommended if they have not already been completed:
Assessment of renal function (measured or estimated GFR; urine protein excretion)
Renal function measured as glomerular filtration rate (GFR) should be monitored at least annually together with the parameters used to stage chronic kidney disease (i.e., blood pressure, hematocrit/hemoglobin, urinary calcium excretion, and serum calcium and phosphorus concentrations). More frequent visits and monitoring for complications of chronic kidney disease (i.e., hypertension, anemia, and secondary hyperparathyroidism) as well as consideration of intensified treatment of cardiovascular risk factors may be indicated if GFR falls below 45 mL/min/1.73 m2 (CKD Stage 3B).
No clinical trials have been registered for Dent disease type 2.
13 publications have been identified in PubMed for Dent disease type 2. Research spans Case Report / Case Series (54%), Review / Meta-Analysis (31%), and Basic Science / Preclinical (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 54% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Dent disease type 2
Lab test results | 4 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Elevated circulating aspartate aminotransferase concentration, Elevated circulating alanine aminotransferase concentration |
Brain and nerves | 2 | Difficulty with thinking and memory (cognitive impairment), Mild global developmental delay |
Growth and development | 1 | Short stature |
Presentation. In the early stages of Dent disease, children (typically ~10 years) may manifest only low molecular weight (LMW) proteinuria and/or hypercalciuria, both of which are usually asymptomatic . In the asymptomatic individual, detection of proteinuria may occur on a urinalysis done for screening or other purposes. LMW proteinuria and/or hypercalciuria can be accompanied by stone disease or nephrocalcinosis, and less frequently by other manifestations of proximal tubular dysfunction including aminoaciduria, phosphaturia, and glycosuria .
Source: GeneReviews — "Dent Disease"
CLCN5. Genotype-phenotype correlations have yet to be established. OCRL. It has been suggested that pathogenic variants in OCRL are associated with a phenotypic spectrum ranging from Lowe syndrome at the severe end to Dent disease 2 at the mild end. Note: Although the renal tubulopathy in Lowe syndrome (which is mainly characterized by altered protein reabsorption) and Dent disease is similar, it is generally milder in Dent disease. Of note, this milder Dent disease phenotype could not be attributed to lesser protein expression or enzyme activity.
Source: GeneReviews — "Dent Disease"
The differential diagnosis of Dent disease includes other causes of proximal tubular dysfunction. Renal Fanconi syndrome. The presence of more generalized proximal tubular dysfunction (glucosuria, amino aciduria, renal tubular acidosis) would suggest the possibility of a renal Fanconi syndrome. Causes of renal Fanconi syndromes can be hereditary (e.g., Wilson disease, glycogen storage disease) or acquired (e.g., exposure to heavy metal, toluene, or cisplatin). Glomerular disease. Some individuals with Dent disease 1 with more severe proteinuria were found to have focal segmental glomerulosclerosis (FSGS) or global sclerosis on kidney biopsy . Most cases of FSGS are idiopathic, but FSGS can be seen in association with obesity or progressive chronic kidney disease of any cause.
Source: GeneReviews — "Dent Disease"
Genetic testing for OCRL is available. Testing is considered confirmatory for diagnosis.
Assessment for nephrocalcinosis and kidney stones by imaging studies, typically low-dose noncontrast CT scan or ultrasound
For those with evidence of renal stones or nephrocalcinosis, urine studies for kidney stone risk factors (including calcium and citrate excretion)
Assessment of risk for bone disease (serum calcium, phosphorus, and alkaline phosphatase)
Note: Elevated alkaline phosphatase has been reported in all individuals with clinical rickets . For those with evidence of bone disease and/or growth delay, more complete assessment of bone health (i.e., serum vitamin D concentration and PTH level; x-ray of long bones for evidence of osteomalacia)
In children, evaluation of stature using standard growth charts. If short stature is present, evaluation by an endocrinologist for the possibility of growth hormone therapy can be considered.
Evaluation for intellectual disability
Careful eye exam for cataracts, especially if there is any concern for visual impairment
Consultation with a clinical geneticist and/or genetic counselor
Although it is not necessary to specifically screen for the possibility, elevated serum muscle enzyme levels are often seen in patients with Dent disease.
Source: GeneReviews — "Dent Disease"
Exposure to potential renal toxins (nonsteroidal anti-inflammatory drugs, aminoglycoside antibiotics, and intravenous contrast agents) should be avoided, especially if renal function is below 45 mL/min/1.73 m2 (CKD stage 3B).
Source: GeneReviews — "Dent Disease"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Dent Disease"
View trials for Dent disease type 2
Phenotype severity distribution: 2 always present features, 7 common features.
Estimated prevalence: Unknown (Unknown prevalence).
4 |
31% |
Laboratory research | 1 | 8% |
Disease patterns and progression | 1 | 8% |
Yang EM (2026). [PMID: 42000952](https://pubmed.ncbi.nlm.nih.gov/42000952/). *Pediatr Nephrol*. [Case Report / Case Series]
Del Prete D (2026). [PMID: 41480250](https://pubmed.ncbi.nlm.nih.gov/41480250/). *Case Rep Nephrol Dial*. [Case Report / Case Series]
Brewer ED (2025). [PMID: 41278199](https://pubmed.ncbi.nlm.nih.gov/41278199/). *Front Cell Dev Biol*. [Review / Meta-Analysis]
Che R (2025). [PMID: 40420588](https://pubmed.ncbi.nlm.nih.gov/40420588/). *J Biomed Res*. [Case Report / Case Series]
Zhou L (2025). [PMID: 41361832](https://pubmed.ncbi.nlm.nih.gov/41361832/). *Ital J Pediatr*. [Epidemiology / Natural History]
Jiang X (2025). [PMID: 40133227](https://pubmed.ncbi.nlm.nih.gov/40133227/). *Ren Fail*. [Case Report / Case Series]
Sakakibara N (2025). [PMID: 40163114](https://pubmed.ncbi.nlm.nih.gov/40163114/). *Pediatr Nephrol*. [Review / Meta-Analysis]
Lowe M (2025). [PMID: 40778266](https://pubmed.ncbi.nlm.nih.gov/40778266/). *Front Cell Dev Biol*. [Review / Meta-Analysis]
de Sa A (2025). [PMID: 40618840](https://pubmed.ncbi.nlm.nih.gov/40618840/). *Biochim Biophys Acta Mol Cell Biol Lipids*. [Review / Meta-Analysis]
Rossanti R (2025). [PMID: 40485688](https://pubmed.ncbi.nlm.nih.gov/40485688/). *Kidney Int Rep*. [Basic Science / Preclinical]